Spexis AG (XSWX:SPEX) Change In Receivables : CHF0.68 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Change In Receivables?

Spexis AG's change in receivables for the quarter that ended in Dec. 2023 was CHF0.02 Mil. It means Spexis AG's Accounts Receivable declined by CHF0.02 Mil from Jun. 2023 to Dec. 2023 .

Spexis AG's change in receivables for the fiscal year that ended in Dec. 2023 was CHF0.68 Mil. It means Spexis AG's Accounts Receivable declined by CHF0.68 Mil from Dec. 2022 to Dec. 2023 .

Spexis AG's Accounts Receivable for the quarter that ended in Dec. 2023 was CHF0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Spexis AG's liquidation value for the six months ended in Dec. 2023 was CHF-14.05 Mil.

Spexis AG Change In Receivables Historical Data

The historical data trend for Spexis AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Change In Receivables Chart

Spexis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.10

0.04

-0.04

0.60

0.68

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial													-0.03	0.27	0.33	0.66	0.02

Spexis AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.68 Mil.

Spexis AG (XSWX:SPEX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Spexis AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Spexis AG's accounts receivable are only considered to be worth 75% of book value:

Spexis AG's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.445	-	14.49	+	0.75 * 0	+	0.5 * 0
=	-14.05

Spexis AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Spexis AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines